Nephros (Nasdaq: NEPH) announced today that it has acquired almost all of the assets of Rockville, Md.–based GenArraytion.
The financial terms of the deal were not disclosed.
Nephros officials said the purchase will give their company access to a host of GenArraytion proprietary assays, multiplexing technology, and selection methods for detecting waterborne pathogens and other microorganisms through polymerase chain reaction (PCR) technology.
South Orange, N.J.–based Nephros provides filtration and pathogen detection solutions to the medical and commercial markets.
“The strategic acquisition of GenArraytion further cements our position in the emerging PCR testing market for waterborne pathogens, expanding our abilities to detect and mitigate the spread of infectious disease in premise plumbing,” Nephros CEO Andy Astor said in a news release.
“In addition to acquiring GenArraytion’s MultiFlex bioassays and other technologies, Dr. R. Paul Schaudies, GenArraytion’s chief executive officer, will partner with our own Dr. Kimothy Smith, VP of Pathogen Detection Systems. Working together, our unified organization will provide customers the ability to use on-site testing with fast, accurate, and actionable data as part of their water management programs.”